ATLANTA, July 16, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its contract for the use of RevID with a 425-bed, Oracle-EHR based health system and extended the term for an additional 5 years.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation accelerates cash flow by ensuring that providers can accurately capture, bill and ultimately be paid for all the care they provide.
“We are pleased with the continued trust our client places in our products and our team,” stated Ben Stilwill, President and Chief Executive Officer, Streamline. “We look forward to supporting their quest to be accurately paid for all of the care they’ve provided and sharing their experience with future clients.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net

| Last Trade: | US$5.33 |
| Daily Volume: | 0 |
| Market Cap: | US$23.240M |
May 01, 2025 January 22, 2025 December 18, 2024 | |

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load